Welcome to LookChem.com Sign In|Join Free

CAS

  • or

261925-02-4

Post Buying Request

261925-02-4 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

261925-02-4 Usage

General Description

3-((methylsulfonyl)methyl)aniline is a chemical compound with the molecular formula C9H13NO2S. It is an aniline derivative with a methylsulfonyl group attached to the carbon atom adjacent to the aniline moiety. 3-((methylsulfonyl)methyl)aniline is often used as an intermediate in the synthesis of pharmaceuticals, dyes, and other organic compounds. It is a colorless to pale yellow liquid with a faint odor and is soluble in most organic solvents. 3-((methylsulfonyl)methyl)aniline is also known for its potential health hazards, as it is considered a skin and eye irritant and may cause respiratory irritation if inhaled. Therefore, proper safety precautions should be taken when handling this chemical.

Check Digit Verification of cas no

The CAS Registry Mumber 261925-02-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,1,9,2 and 5 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 261925-02:
(8*2)+(7*6)+(6*1)+(5*9)+(4*2)+(3*5)+(2*0)+(1*2)=134
134 % 10 = 4
So 261925-02-4 is a valid CAS Registry Number.

261925-02-4Relevant articles and documents

Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer

Lücking, Ulrich,Kosemund, Dirk,B?hnke, Niels,Lienau, Philip,Siemeister, Gerhard,Denner, Karsten,Bohlmann, Rolf,Briem, Hans,Terebesi, Ildiko,B?mer, Ulf,Sch?fer, Martina,Ince, Stuart,Mumberg, Dominik,Scholz, Arne,Izumi, Raquel,Hwang, Stuart,Von Nussbaum, Franz

, p. 11651 - 11674 (2021/07/31)

Selective inhibition of exclusively transcription-regulating positive transcription elongation factor b/CDK9 is a promising new approach in cancer therapy. Starting from atuveciclib, the first selective CDK9 inhibitor to enter clinical development, lead optimization efforts aimed at identifying intravenously (iv) applicable CDK9 inhibitors with an improved therapeutic index led to the discovery of the highly potent and selective clinical candidate VIP152. The evaluation of various scaffold hops was instrumental in the identification of VIP152, which is characterized by the underexplored benzyl sulfoximine group. VIP152 exhibited the best preclinical overall profile in vitro and in vivo, including high efficacy and good tolerability in xenograft models in mice and rats upon once weekly iv administration. VIP152 has entered clinical trials for the treatment of cancer with promising longterm, durable monotherapy activity in double-hit diffuse large B-cell lymphoma patients.

Aniline pyrimidines, its preparation method and medical use (by machine translation)

-

, (2018/03/01)

The invention relates to: an aniline pyrimidine compound represented as the formula (I), a medicinal salt thereof, a prodrug thereof, and a hydrate or solvate thereof and also relates to: the preparation method of the compound, a medicine composition comp

FLUORINATED BENZOFURANYL-PYRIMIDINE DERIVATIVES CONTAINING A SULFONE GROUP

-

, (2016/05/24)

The present invention relates to fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disord

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 261925-02-4